BRSYF (BrainsWay) ROE % Adjusted to Book Value: 1.96% (As of Mar. 2026)

BrainsWay BRSYF 70 ROE % Adjusted to Book Value is 1.96% as of Mar. 2026. GuruFocus rates BRSYF with a GF Score™ of 70/100 and a GF Value™ of $6.24. The stock has 6 warning signs investors should review.

BrainsWay's ROE % for the quarter that ended in Mar. 2026 was 12.30%. BrainsWay's PB Ratio for the quarter that ended in Mar. 2026 was 6.27. BrainsWay's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 1.96%.

BrainsWay ROE % Adjusted to Book Value Related Terms

BrainsWay ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BrainsWay's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrainsWay ROE % Adjusted to Book Value Chart

BrainsWay Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-7.30

-39.38

-6.35

2.96

2.39

BrainsWay Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															2.05	6.51	3.04	3.51	1.96

BRSYF vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, BrainsWay's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BrainsWay ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BrainsWay's ROE % Adjusted to Book Value falls into.

Save Embed

70GF Score

BrainsWay Ltd BRSYF

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BrainsWay ROE % Adjusted to Book Value Calculation

BrainsWay's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	11.18%	/	4.67
	=	2.39%

BrainsWay's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	12.30%	/	6.27
	=	1.96%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 1.96% mean?

BrainsWay (BRSYF) has a ROE % Adjusted to Book Value of 1.96% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BrainsWay and its competitors.

Is BrainsWay's ROE % Adjusted to Book Value too high?

BrainsWay's current ROE % Adjusted to Book Value is 1.96%. Overall, BrainsWay has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.

How does BrainsWay's ROE % Adjusted to Book Value compare to ABT and SYK?

BrainsWay's ROE % Adjusted to Book Value of 1.96% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?

A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BrainsWay and its competitors. BrainsWay's current ROE % Adjusted to Book Value is 1.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BrainsWay stock overvalued right now?

BrainsWay (BRSYF) has a current ROE % Adjusted to Book Value of 1.96%. The stock's GF Value™ is $6.24, compared to a current price of $13.55 — trading 117.1% above its estimated fair value. The current ROE % Adjusted to Book Value is 1.96%. BrainsWay's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For BrainsWay (BRSYF), the current ROE % Adjusted to Book Value is 1.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BrainsWay (BRSYF) Overvalued in 2026?

Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued. The current stock price of $13.55 is trading 117.1% above its estimated GF Value™ of $6.24.

Key valuation signals for BRSYF:

ROE % Adjusted to Book Value: 1.96%
GF Value™: $6.24 vs. price of $13.55 (117.1% above fair value)
GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BRSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BrainsWay Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XTAE:SOFW XTAE:ILX XTAE:ABOU XTAE:EPIT XTAE:PLSM XTAE:ALMD XTAE:ERKA XTAE:BIOV XTAE:EFNC-M XTAE:HUMX-M ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges BWAY:USA BWAY:Israel

Address 16 Hartum Street, 14th Floor, RAD Tower, Har HaHotzvim, Jerusalem, ISR, 9777516

Website https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

70GF Score

Get the complete analysis for BRSYF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.55

Price

$6.24

GF Value

View BRSYF Analysis

See ROE % Adjusted to Book Value data for all stocks →